TY - JOUR
T1 - Toward defining the preclinical stages of Alzheimer's disease
T2 - Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
AU - Sperling, Reisa A.
AU - Aisen, Paul S.
AU - Beckett, Laurel A.
AU - Bennett, David A.
AU - Craft, Suzanne
AU - Fagan, Anne M.
AU - Iwatsubo, Takeshi
AU - Jack, Clifford R.
AU - Kaye, Jeffrey
AU - Montine, Thomas J.
AU - Park, Denise C.
AU - Reiman, Eric M.
AU - Rowe, Christopher C.
AU - Siemers, Eric
AU - Stern, Yaakov
AU - Yaffe, Kristine
AU - Carrillo, Maria C.
AU - Thies, Bill
AU - Morrison-Bogorad, Marcelle
AU - Wagster, Molly V.
AU - Phelps, Creighton H.
PY - 2011/5
Y1 - 2011/5
N2 - The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious.
AB - The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious.
KW - Amyloid
KW - Biomarker
KW - Neurodegeneration
KW - Preclinical Alzheimer's disease
KW - Prevention
UR - http://www.scopus.com/inward/record.url?scp=79956098248&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2011.03.003
DO - 10.1016/j.jalz.2011.03.003
M3 - Article
C2 - 21514248
AN - SCOPUS:79956098248
VL - 7
SP - 280
EP - 292
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
SN - 1552-5260
IS - 3
ER -